4K Broadcasting

Innovative Delivery: Comprehensive Analysis of ‘Magic Bullet’ ADC Drug Screening

by
Innovative Delivery: Comprehensive Analysis of 'Magic Bullet' ADC Drug Screening

Authors: Li Jiaxing, Hu Linghong, Hu YuhaoImages: Yang Zhenzhen1. Summary Antibody-drug conjugates (ADCs) rejuvenate the concept of targeted chemotherapy by coupling cytotoxic payloads to antibodies. The first stage of the complex intracellular toxin delivery process of ADCs is endocytosis. Analyzing the endocytosis of target receptors and ADCs can greatly enhance preclinical studies, clinical translation, and … Read more

Experiences and Lessons in ADC Clinical Development

by
Experiences and Lessons in ADC Clinical Development

After nearly 30 years of development, the ADC platform has been established, with 12 approved products by the FDA and many more in development. This article aims to provide guidance for clinical researchers on the effective design of clinical protocols and the lessons learned from ADCs. 01Introduction In cancer treatment, compared to novel immunotherapy targets … Read more

Available ADC Drugs for Breast Cancer Patients

by
Available ADC Drugs for Breast Cancer Patients

IntroductionIn the field of breast cancer treatment, antibody-drug conjugates (ADC) are gradually becoming an important therapeutic approach.ADC drugs are a new type of cancer treatment that combines the targeting capability of antibodies with the potent killing power of chemotherapy drugs, allowing for precise delivery of chemotherapy agents to cancer cells, thereby improving efficacy and reducing … Read more

How to Address 8 Common Adverse Reactions of ADC Drugs?

by

With the recent approvals of Trastuzumab emtansine (T-DM1) and Gemtuzumab ozogamicin in China, the review of Trastuzumab deruxtecan (T-DXd, DS-8201) is progressing steadily, marking the arrival of a “future” where antibody-drug conjugates (ADCs) greatly benefit breast cancer patients in China. ADCs achieve “precision targeting” of tumors and are referred to as “magic bullets,” changing the … Read more

Understanding The Mechanism Of ADC Drugs Against Tumors

by
Understanding The Mechanism Of ADC Drugs Against Tumors

Following the era of chemotherapy, targeted therapy, and immunotherapy, cytotoxic drugs conjugated with targeted monoclonal antibodies have opened a new era in tumor treatment with the ADC drug class, achieving remarkable results. They have now become a significant category of new drugs in cancer treatment both domestically and internationally. So what exactly are ADC drugs? … Read more

Training Recommendation | Analysis of ADC Clinical Development Path and Registration Strategies

by

Organizer China Chemical Enterprise Management Association Pharmaceutical Chemical Committee Yaocheng Material Information Technology (Beijing) Co., Ltd. Relevant Units Antibody-drug conjugates (ADCs) have become a major focus in pharmaceutical research and development in recent years. As of the end of 2023, 15 ADC drugs have been approved for marketing worldwide, and over 900 ADC drugs are … Read more

Discussion on Off-Target Toxicity Mechanisms of ADC Drugs

by
Discussion on Off-Target Toxicity Mechanisms of ADC Drugs

ADC drugs utilize monoclonal antibodies to specifically deliver cytotoxic drugs to tumor cells, characterized by precise targeting and specific killing of tumors, thereby limiting the exposure of cytotoxic drugs to normal cells or tissues. The main clinical toxicities of ADC drugs include gastrointestinal, hematological, hepatic, neurological, and ocular toxicities, which are usually dose-limiting[2]. Depending on … Read more

Clinical Results of Targeting Prostate Cancer with ADCs

by
Clinical Results of Targeting Prostate Cancer with ADCs

Important targets for targeting prostate cancer (PCa) include: prostate-specific membrane antigen (PSMA), six-transmembrane epithelial antigen 1 (STEAP-1), solute carrier family 44 member 4 (SLC44A4), trophoblast cell surface antigen (Trop-2) and B7-H3. Introduction Antibody-drug conjugates (ADCs) consist of a linker, payload, and monoclonal antibody (mAb). They combine the advantages of high specificity targeting and potent killing … Read more

Discussing Immunogenicity of ADCs

by
Discussing Immunogenicity of ADCs

▉ Introduction Protein drugs have the potential to induce immunogenicity, which can affect efficacy and even endanger life. New paradigms in biotherapy, such as antibody-drug conjugates (ADC), fusion proteins, and pegylation carry non-native human protein sequences and/or structural motifs, which may increase their immunogenicity risk. Therefore, comprehensive risk assessment, strategies, and analysis are needed to … Read more

Exploring the Stories Behind ADC Payloads: Traditional Chemotherapeutics

by
Exploring the Stories Behind ADC Payloads: Traditional Chemotherapeutics

Although the concept of antibody-drug conjugates (ADCs) seems straightforward, developing successful and effective drugs involves numerous challenges. For a successful ADC product, scientists must optimize various parameters, including ADC stability (for instance, the drug payload should not be released before the ADC reaches its target in the body), pharmacokinetics (e.g., the payload should not accumulate … Read more